Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mentor’s Stock Jumps In Q3 On Silicone Implant “Approvable” Letter

This article was originally published in The Gray Sheet

Executive Summary

FDA's "approvable" letter to Mentor for the Memory Gel silicone breast implants drove the firm's stock up 32.6% to $55.01 for the quarter, but investor tunnel-vision could keep future stock movement tied to FDA's final decision

You may also be interested in...



Earnings In Brief

CryoCath's AF results: Arctic Front cryoablation system with FlexCath deflectable sheath to treat atrial fibrillation achieved a chronic efficacy rate of over 80% at 6 months in a 20-patient U.S. trial, according to CryoCath CEO Steve Arless. The firm reported no long-term safety issues, though two patients did have to be re-treated early on. "If the data continue to build as with the first 20 patients, we'll certainly corner the vast majority of the [atrial fibrillation] market. But the interesting thing we will address longer term is what role [Arctic Front] will play in the treatment of ventricular tachycardia, where implantable defibrillators play a huge role right now," Arless said. For the quarter ended Dec. 31, the firm reported revenue of $8.9 mil., up 48% over the prior-year period...

Earnings In Brief

CryoCath's AF results: Arctic Front cryoablation system with FlexCath deflectable sheath to treat atrial fibrillation achieved a chronic efficacy rate of over 80% at 6 months in a 20-patient U.S. trial, according to CryoCath CEO Steve Arless. The firm reported no long-term safety issues, though two patients did have to be re-treated early on. "If the data continue to build as with the first 20 patients, we'll certainly corner the vast majority of the [atrial fibrillation] market. But the interesting thing we will address longer term is what role [Arctic Front] will play in the treatment of ventricular tachycardia, where implantable defibrillators play a huge role right now," Arless said. For the quarter ended Dec. 31, the firm reported revenue of $8.9 mil., up 48% over the prior-year period...

Groups Differ On Impact Of Silicone Breast Implants On Subgroup Populations

Several women's health advocates are concerned about a dearth of data on the effect of silicone breast implants on different patient subgroups, including African American women and breast cancer survivors, though some plastic surgeons suggest that these worries are overblown

Related Content

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel